EGFR and small cell lung carcinoma: Unlike lung adenocarcinoma, which is frequently driven by druggable alterations such as activating mutations in EGFR, ALK, and KRAS6,7, SCLC is driven mostly by unactionable, loss-of-function mutations in genes encoding tumor suppressors, including RB1 and P538.